HOME >> MEDICINE >> NEWS
OREXIGEN reports positive 24-week results for Contrave phase III obesity treatment study

San Diego, CA, September 26, 2006 -- OREXIGENTM Therapeutics, Inc., a privately held clinical-stage neuroscience company developing novel strategic approaches to the treatment of obesity, today announced that top line results for the company's lead obesity compound, ContraveTM, demonstrated significant advantages in weight loss in a 24-week multi-center, placebo-controlled phase III trial; the trial will continue unblinded for an additional 24 weeks.

Contrave is a proprietary combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, with one of several different doses of naltrexone, an opioid antagonist used to treat various addictive disorders. The bupropion/naltrexone combination is based on the company's underlying research into the brain's regulation of appetite and energy expenditure, which suggests that combining these two central nervous system drugs may improve the ability to initiate weight loss, and importantly, to continue weight loss by blocking the body's attempts to compensate for weight loss during the treatment. The trial is testing three different dosages of naltrexone combined with the same dosage of bupropion. In what may become the preferred dose pairing based on performance and tolerability, patients completing the 24-week trial using Contrave experienced on average an excess of 7% weight loss from baseline compared to approximately 1% weight loss from baseline on average for patients using the placebo. In addition, the Contrave combination outperformed either naltrexone or bupropion given alone, and the Contrave-associated weight loss trajectory showed no indication of reaching a plateau at the conclusion of 24 weeks of blinded therapy. These findings for Contrave are consistent with an earlier phase II proof of concept study presented at the annual meeting of the American Diabetes Association in June.

"These clinical findings are indicative of a therapeutic synergy when combi
'"/>

Contact: Stephen Gendel
sgendel@biocompartners.com
212-918-4650
BioCom Partners
26-Sep-2006


Page: 1 2 3

Related medicine news :

1. New study reports hotel guests at risk from carbon monoxide poisoning
2. MIT reports key pathway in synaptic plasticity
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. New study reports improved treatment and reduced mortality for patients with heart failure
5. Study reports changing to a low-fat diet can induce stress
6. Arsenic in chicken feed may pose health risks to humans, C&EN reports
7. Tai Chi boosts immunity to shingles virus in older adults, NIH-sponsored study reports
8. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
9. UCLA study reports conflict of interest policies and practices of major journals
10. New study on school bus safety shows injuries well exceed previous reports
11. Drug company reports should be read with caution, warn doctors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
Breaking Medicine Technology:
Cached News: